1. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm. Hum Pathol 2011; 42(7): 918–931.
2. Gates MA, Rosner BA, Hecht JL et al. Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype. Am J Epidemiol 2010; 171(1): 45–53.
3. Cramer DW. The Epidemiology of Endometrial and Ovarian Cancer. Hematology-Oncology Clinics of North America 2012; 26(1): 1–12.
4. Gram IT, Lukanova A, Brill I et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer 2012; 130(9): 2204–2210.
5. Jemal A, Siegel R, Xu JQ et al. Cancer Statistics 2010. CA Cancer J Clin 2010; 60(5): 277–300.
6. Jaarsveld MTM van, Helleman J, Berns EMJJ et al. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010; 42(8): 1282–1290.
7. Salani R, Backes FJ, Fung MFK et al: Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204(6): 466–478.
8. Skates SJ, Mai P, Horick NK et al. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prev Res 2011; 4(9): 1401–1408.
9. Záveský L. CA125/MUC16 jako diagnostický a prognostický marker pro karcinom ovaria. Onkologie (Solen) 2012; 6(2): 65–67.
10. Buys SS, Partridge E, Black A et al. Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305(22): 2295–2303.
11. Jacob F, Meier M, Caduff R et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011; 121(3): 487–491.
12. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3): 143–159.
13. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010; 16 (6): 257–267.
14. Scott GK, Mattie ND, Berger CE et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66(3): 1277–1281.
15. Weber JA, Baxter DH, Zhang SL et al. The MicroRNA Spectrum in 12 Body Fluids Clin Chem 2010; 56(11): 1733–1741.
16. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110(1): 13–21.
17. Bussing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008; 14(9): 400–409.
18. Brueckner B, Stresemann C, Kuner R et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007; 67(4): 1419–1423.
19. Bendoraite A, Knouf EC, Garg KS et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010; 116 (1): 117–125.
20. Wu QH, Guo RJ, Lin M, et al. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol 2011; 122(1): 149–154.
21. Resnick KE, Alder H, Hagan JP et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112(1): 55–59.
22. Häusler SFM, Keller A, Chandran PA et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010; 103(5): 693–700.
23. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67(18): 8699–8707.
24. Dahiya N, Sherman-Baust CA, Wang TL, et al. MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer. Plos One 2008; 3(6): e2436.
25. Nam EJ, Yoon HJ, Kim SW et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14(9): 2690–2695.
26. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68(2): 425–433.
27. Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries. Plos One 2009; 4(4): e5311.
28. Gallagher MF, Flavin RJ, Elbaruni SA, et al. Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res 2009; 2: 19.
29. Laios A, O‘Tooles, Flavin R, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008; 7: 35.
30. Záveský L, Jančárková N, Kohoutová M. Ovarian cancer: Origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 2011; 58(6): 457–468.